HIV-1, reactive oxygen species, and vascular complications

Free Radical Biology and Medicine

Volumn 53, Issue 1, 2012, Pages 143-159

  Porter, Kristi M ^a   Sutliff, Roy L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Antiretroviral therapy; Atherosclerosis; Free radicals; HIV 1; HIV 1 proteins; Oxidative stress; Pulmonary hypertension; Reactive oxygen species

Indexed keywords

AMPRENAVIR; ANTIOXIDANT; ANTIRETROVIRUS AGENT; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; HYDROGEN PEROXIDE; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEINASE INHIBITOR; RALTEGRAVIR; REACTIVE OXYGEN METABOLITE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SUPEROXIDE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION SENSITIVITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; VASCULAR DISEASE;

HIV INFECTIONS; HIV-1; HUMANS; REACTIVE OXYGEN SPECIES; VASCULAR DISEASES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861713637     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.03.019     Document Type: Review

References (294)

1. F.J.J. Palella, R.K. Baker, A.C. Moorman, J.S. Chmiel, K.C. Wood, J.T. Brooks, and S.D. Holmberg HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study J Acquired Immune Defic Syndr 43 2006 27 34
2. D.M. Corey, H.W. Kim, R. Salazar, R. Illescas, J. Villena, L. Gutierrez, J. Sanchez, and S.R. Tabet Effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study J. Acquired Immune Defic Syndr 44 2007 451 455
3. J. Neuhaus, B. Angus, J.D. Kowalska, A.L. Rosa, J. Sampson, D. Wentworth, and A. Mocroft INSIGHT SMART and ESPRIT Study groups. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV AIDS 24 2010 697 706
4. G. Barbaro Cardiovascular manifestations of HIV infection Circulation 106 2002 1420 1425
5. G. Krishnaswamy, D.S. Chi, J.L. Kelley, F. Sarubbi, J.K. Smith, and A. Peiris The cardiovascular and metabolic complications of HIV infection Cardiol Rev 8 2000 260 268
6. P.Y. Hsue, J.C. Lo, A. Franklin, A.F. Bolger, J.N. Martin, S.G. Deeks, and D.D. Waters Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection Circulation 109 2004 1603 1608
7. P.Y. Hsue, A.F. Bolger, and J.N. Martin Pulmonary hypertension in HIV-infected individuals Clin Infect Dis 53 2011 96
8. N.F. Crum, R.H. Riffenburgh, S. Wegner, B.K. Agan, S.A. Tasker, K.M. Spooner, A.W. Armstrong, S. Fraser, and M.R. Wallace Triservice AIDS clinical consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras J Acquired Immune Defic Syndr 41 2006 194 200
9. E.C. Seaberg, L. Benning, A.R. Sharrett, J.M. Lazar, H.N. Hodis, W.J. Mack, M.J. Siedner, J.P. Phair, L.A. Kingsley, and R.C. Kaplan Association between human immunodeficiency virus infection and stiffness of the common carotid artery Stroke 41 2010 2163 2170
10. G. Guaraldi, S. Zona, G. Orlando, F. Carli, G. Ligabue, F. Fiocchi, M. Menozzi, R. Rossi, M.G. Modena, and P. Raggi Human immunodeficiency virus infection is associated with accelerated atherosclerosis J Antimicrob Chemother 66 2011 1857 1860
11. E.K. Weir The United States experience with the acute and chronic treatment of primary pulmonary hypertension Eur Heart J 9 1988 33 38
12. H. Nunes, M. Humbert, O. Sitbon, J.H. Morse, Z. Deng, J.A. Knowles, C. Le Gall, F. Parent, G. Garcia, P. Herve, R.J. Barst, and G. Simonneau Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension Am J Respir Crit Care Med 167 2003 1433 1439
13. N. Petrosillo, P. Chinello, and S. Cicalini Pulmonary hypertension in individuals with HIV infection AIDS 20 2006 2128 2129
14. M. Opravil, M. Pechere, R. Speich, H.I. Joller-Jemelka, R. Jenni, E.W. Russi, B. Hirschel, and R. Luthy HIV-associated primary pulmonary hypertension: a case control study. Swiss HIV Cohort Study Am J Respir Crit Care Med 155 1997 990 995
15. J.X. -J. Yuan, and L.J. Rubin Pathogenesis of pulmonary arterial hypertension Circulation 111 2005 534 538
16. B. Degano, G.M. Savale, L. Montani, D. Jais, X. Yaici, A. Le Pavec, J. Humbert, G. Simmonneau, and O. Sitbon HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era AIDS 24 2010 67 75
17. E. Fontas, F. van Leth, C.A. Sabin, N. Friis-Moller, M. Rickenbach, A. d'Arminio Monforte, O. Kirk, M. Dupon, L. Morfeldt, S. Mateu, K. Petoumenos, W. El-Sadr, S. de Wit, J.D. Lundgren, C. Pradier, and P. Reiss D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 189 2004 1056 1074
18. L.E. Spieker, B. Karadag, C. Binggeli, and R. Corti Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection Heart Vessels 20 2005 171 174
19. P. Maggi, A. Lillo, F. Perilli, R. Maserati, A. Chirianni, and PREVALEAT Group Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study AIDS 18 2004 1023 1028
20. Q. Meng, J.A.C. Lima, H. Lai, D. Vlahov, D.D. Celentano, S.A. Strathdee, K.E. Nelson, K.C. Wu, S. Chen, W. Tong, and S. Lai Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors Am Heart J 144 2002 642 648
21. G. Chironi, L. Escaut, J. Gariepy, A. Cogny, J.-J. Monsuez, J. Levenson, A. Simon, and D. Vittecoq Carotid intima-media thickness in heavily pretreated HIV-infected patients J Acquired Immune Defic Syndr 32 2003 490 493
22. M.G.A. van Vonderen, E.A.M. Hassink, M.A. van Agtmael, C.D.A. Stehouwer, S.A. Danner, P. Reiss, and Y. Smulders Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy J Infect Dis 199 2009 1186 1194
23. G.A. McComsey, M. O'Riordan, S.L. Hazen, D. El-Bejjani, S. Bhatt, M. -L. Brennan, N. Storer, J. Adell, D.A. Nakamoto, and V. Dogra Increased carotid intima media thickness and cardiac biomarkers in HIV infected children AIDS 21 2007 921 927
24. P. Mercié, R. Thiébaut, V. Aurillac-Lavignolle, J.L. Pellegrin, M.C. Yvorra-Vives, C. Cipriano, D. Neau, P. Morlat, J.M. Ragnaud, M. Dupon, F. Bonnet, S. Lawson-Ayayi, D. Malvy, R. Roudaut, and F. Dabis On behalf of the Groupe d'Epidemiologie Clinique du Sida en Aquitaine. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients HIV Med 6 2005 380 387
25. J.S. Currier, M.A. Kendall, R. Zackin, W.K. Henry, B. Alston-Smith, F.J. Torriani, J. Schouten, K. Mickelberg, Y. Li, and H.N. Hodis AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure AIDS 19 2005 927 933
26. S. Johnsen, S.E. Dolan, K.V. Fitch, J.R. Kanter, L.C. Hemphill, J.M. Connelly, R.S. Lees, H. Lee, and S. Grinspoon Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome J Clin Endocrinol Metab 91 2006 4916 4924
27. M. Masiá, E. Bernal, S. Padilla, N. García, J.C. Escribano, E. Martínez, and F. Gutiérrez A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk J Antimicrob Chemother 64 2009 589 598
28. P.Y. Hsue, P.W. Hunt, A. Schnell, S.C. Kalapus, R. Hoh, P. Ganz, J.N. Martin, and S.G. Deeks Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis AIDS 23 2009 1059 1067
29. D. Bonnet, Y. Aggoun, I. Szezepanski, N. Bellal, and S.P. Blanche Arterial stiffness and endothelial dysfunction in HIV-infected children AIDS 18 2004 1037 1041
30. K. Sevastianova, J. Sutinen, J. Westerbacka, M. Ristola, and H. Yki-Jarvinen Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy Antiviral Ther 10 2005 925 935
31. U.S. Kristoffersen, K. Kofoed, G. Kronborg, A.K. Giger, A. Kjaer, and A.M. Lebech Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy HIV Med 10 2009 79 87
32. P.Y. Hsue, P.W. Hunt, Y. Wu, A. Schnell, J.E. Ho, H. Hatano, Y. Xie, J.N. Martin, P. Ganz, and S.G. Deeks Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients AIDS 23 2009 2021 2027
33. D. Nolan, G.F. Watts, S.E. Herrmann, M.A. French, M. John, and S. Mallal Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM 96 2003 825 832
34. J.J.R.O. Blanco, I.S.S.R. García, J.G.M. Cerezo, J.M.A.P.A.S.N. de Rivera, P.M. Anaya, P.G.A. Raya, J.G.L. García, J.R.N.A. López, F.J.B. Hernández, and J.J.V.Z. Rodríguez Endothelial function in HIV-infected patients with low or mild cardiovascular risk J Antimicrob Chemother 58 2006 133 139
35. V.V. Joshi, B. Pawel, E. Connor, L. Sharer, J.M. Oleske, S. Morrison, and J. Marin-Garcia Arteriopathy in children with acquired immune deficiency syndrome Pediatr Pathol 7 1987 261 275
36. P. Paton, A. Tabib, R. Loire, and R. Tete Coronary artery lesions and human immunodeficiency virus infection Res Virol 144 1993 225 231
37. B.F. Mandell, and L.H Calabrese Infections and systemic vasculitis Curr Opin Rheumatol 10 1998 51 57
38. M. Cebrian, O. Miro, C. Font, B. Coll-Vinent, and J.M. Grau HIV-related vasculitis AIDS Patient Care STDS 11 1997 245 258
39. A.H. Maniker, and C.D. Hunt Cerebral aneurysm in the HIV patient: a report of six cases Surg Neurol 46 1996 49 54
40. C. Grunfeld, M. Pang, W. Doerrler, J.K. Shigenaga, P. Jensen, and K.R. Feingold Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome J Clin Endocrinol Metab 74 1992 1045 1052
41. J.F. Schved, J.C. Gris, A. Arnaud, P. Martinez, N. Sanchez, J.L. Wautier, and C. Sarlat Von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator J Lab Clin Med 120 1992 411 419
42. A. Lafeuillade, M.C. Alessi, I. Poizot-Martin, C. Boyer-Neumann, C. Zandotti, R. Quilichini, L. Aubert, C. Tamalet, I. Juhan-Vague, and J.A. Gastaut Endothelial cell dysfunction in HIV infection J Acquired Immune Defic Syndr 5 1992 127 131
43. K. Wolf, D.A. Tsakiris, R. Weber, P. Erb, and M. Battegay Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1 J Infect Dis 185 2002 456 462
44. A.J. Greenwood, J. Hughes, G. Wallace, P. Seed, M.R. Stanford, and E.M. Graham Soluble intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in patients with HIV/AIDS does not appear to correlate with cytomegalovirus retinitis Int J STD AIDS 9 1998 713 714
45. M. Seigneur, J. Constans, A. Blann, M. Renard, J.L. Pellegrin, J. Amiral, M. Boisseau, and C. Conri Soluble adhesion molecules and endothelial cell damage in HIV infected patients Thromb Haemostasis 77 1997 646 649
46. D. Klein, L.B. Hurley, C.P. Quesenberry Jr, and S. Sidney Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquired Immune Defic Syndr 30 2002 471 477
47. V.A. Triant, H. Lee, C. Hadigan, and S.K. Grinspoon Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease J Clin Endocrinol Metab 92 2007 2506 2512
48. W.M. El-Sadr, J.D. Lundgren, J.D. Neaton, F. Gordin, D. Abrams, R.C. Arduino, A. Babiker, W. Burman, N. Clumeck, C.J. Cohen, D. Cohn, D. Cooper, J. Darbyshire, S. Emery, G. Fatkenheuer, B. Gazzard, B. Grund, J. Hoy, K. Klingman, M. Losso, N. Markowitz, J. Neuhaus, A. Phillips, and C. Rappoport CD4 count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296
49. A. Blum, V. Hadas, M. Burke, I. Yust, and A. Kessler Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction Clin Cardiol 28 2005 149 153
50. A. Solages, J.A. Vita, D.J. Thornton, J. Murray, T. Heeren, D.E. Craven, and C.R. Horsburgh Jr Endothelial function in HIV-infected persons Clin Infect Dis 42 2006 1325 1332
51. D. Bonnet, Y. Aggoun, I. Szezepanski, N. Bellal, and S. Blanche Arterial stiffness and endothelial dysfunction in HIV-infected children AIDS 18 2004 1037 1041
52. U. Oliviero, G. Bonadies, V. Apuzzi, M. Foggia, G. Bosso, S. Nappa, A. Valvano, E. Leonardi, G. Borgia, G. Castello, R. Napoli, and L. Saccà Human immunodeficiency virus per se exerts atherogenic effects Atherosclerosis 204 2009 586 589
53. M.W. Lorenz, C. Stephan, A. Harmjanz, S. Staszewski, A. Buehler, M. Bickel, S. von Kegler, D. Ruhkamp, H. Steinmetz, and M. Sitzer Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis Atherosclerosis 196 2008 720 726
54. M.G. van Vonderen, Y.M. Smulders, C.D. Stehouwer, S.A. Danner, C.M. Gundy, F. Vos, P. Reiss, and M.A. Agtmael Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy J Acquired Immune Defic Syndr 50 2009 153 161
55. A. Mandas, E.L. Iorio, M.G. Congiu, C. Balestrieri, A. Mereu, D. Cau, S. Dessí, and N. Curreli Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy J Biomed Biotechnol 2009 2009 749575
56. D.R. Suresh, V. Annam, K. Pratibha, and B.V. Prasad Total antioxidant capacity - a novel early bio-chemical marker of oxidative stress in HIV infected individuals J Biomed Sci 16 2009 61
57. A. Sonnerborg, G. Carlin, B. Akerlund, and C. Jarstrand Increased production of malondialdehyde in patients with HIV infection Scand J Infect Dis 20 1988 287 290
58. J.P. Revillard, C.M. Vincent, A.E. Favier, M.J. Richard, M. Zittoun, and M.D. Kazatchkine Lipid peroxidation in human immunodeficiency virus infection J. Acquired Immune Defic Syndr 5 1992 637 638
59. Y.W.R. Wang Potential therapeutics of vitamin E (tocopherol) in AIDS and HIV Drugs 48 1994 327 338
60. C.J. Lacey, M.E. Murphy, M.J. Sanderson, E.F. Monteiro, A. Vail, and C.J. Schorah Antioxidant-micronutrients and HIV infection Int. J. STD AIDS 7 1996 485 489
61. R.J.H. Buhl, K.J. Holroyd, F.B. Wells, A. Mastrangeli, C. Saltini, A.M. Cantin, and R.G. Crystal Systemic glutathione deficiency in symptom-free HIV-seropositive individuals Lancet 2 1989 1294 1298
62. H.P. Eck, H. Gmunder, M. Hartmann, D. Petzoldt, V. Daniel, and W. Droge Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1 infected patients Biol Chem Hoppe Seyler 370 1989 101 108
63. F.J.T. Staal, S.W. Ela, M. Roederer, M.T. Anderson, and L.A. Herzenberg Glutathione deficiency and human immunodeficiency virus infection Lancet 339 1992 909 912
64. F.J.R.M. Staal, D.M. Israelski, J. Bubp, L.A. Mole, D. McShane, S.C. Deresinski, W. Ross, H. Sussman, and P.A. Raju Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals AIDS Res Hum Retroviruses 81 1992 305 311
65. A.S.V.R. Wanchu, S. Pallikkuth, and R.K. Sachdeva Oxidative stress in HIV-infected individuals: a cross-sectional study AIDS Res Hum Retroviruses 25 2009 1307 1311
66. H. Nakamura, S. De Rosa, M. Roederer, M.T. Anderson, J.G. Dubs, J. Yodoi, A. Holmgren, L.A. Herzenberg, and L.A. Herzenberg Elevation of plasma thioredoxin levels in HIV-infected individuals Int Immunol 8 1996 603 611
67. W.H. Watson, X. Yang, Y.E. Choi, D.P. Jones, and J.P. Kehrer Thioredoxin and its role in toxicology Toxicol Sci 78 2004 3 14
68. S. Aquaro, C. Muscoli, A. Ranazzi, M. Pollicita, T. Granato, L. Masuelli, A. Modesti, C. -F. Perno, and V. Mollace The contribution of peroxynitrite generation in HIV replication in human primary macrophages Retrovirology 4 2007 76
69. M. Husain, L.G. Meggs, H. Vashistha, S. Simoes, K.O. Griffiths, D. Kumar, J. Mikulak, P.W. Mathieson, M.A. Saleem, L. Del Valle, S. Pina-Oviedo, J.Y. Wang, S.V. Seshan, A. Malhotra, K. Reiss, and P.C. Singhal Inhibition of p66ShcA longevity gene rescues podocytes from HIV-1-induced oxidative stress and apoptosis J Biol Chem 284 2009 16648 16658
70. J. Choi, R. -M. Liu, R.K. Kundu, F. Sangiorgi, W. Wu, R. Maxson, and H.J. Forman Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice J Biol Chem 275 2000 3693 3698
71. E.R. Kline, D.J. Kleinhenz, B. Liang, S. Dikalov, D.M. Guidot, C.M. Hart, D.P. Jones, and R.L. Sutliff Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration Am J Physiol Heart Circ Physiol 294 2008 H2792 H2804
72. C. Lassiter, X. Fan, P. Joshi, B. Jacob, R. Sutliff, D. Jones, M. Koval, and D. Guidot HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction AIDS Res Ther 6 2009 1
73. B.A. Jacob, K.M. Porter, S.C. Elms, P.-Y. Cheng, D.P. Jones, and R.L. Sutliff HIV-1-induced pulmonary oxidative and nitrosative stress: exacerbated response to endotoxin administration in HIV-1 transgenic mouse model Am J Physiol Lung Cell Mol Physiol 291 2006 L811 L819
74. M.R. Sadaie, J. Rappaport, T. Benter, S.F. Josephs, R. Willis, and F. Wong-Staal Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor Proc Natl Acad Sci USA 85 1988 9224 9228
75. A.D. Frankel, and J.A.T. Young HIV-1: fifteen proteins and an RNA Annu Rev Biochem 67 1998 1 25
76. B. Ensoli, L. Buonaguro, G. Barillari, V. Fiorelli, R. Gendelman, R.A. Morgan, P. Wingfield, and R.C. Gallo Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation J Virol 67 1993 277 287
77. M. Westendorp, R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K. Debatin, and P. Krammer Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120 Nature 375 1995 497 500
78. D.E. Helland, J.L. Welles, A. Caputo, and W.A. Haseltine Transcellular transactivation by the human immunodeficiency virus type 1 tat protein J Virol 65 1991 4547 4549
79. A. Marcuzzi, J. Weinberger, and O.K. Weinberger Transcellular activation of the human immunodeficiency virus type 1 long terminal repeat in cocultured lymphocytes J Virol 66 1992 4228 4232
80. Westendorp, M.; Shatrov, V.A.; Schulze-Osthoff; K.; Frank, R.; Kraft, M.; Los, M.; Krammer, P.H.; Droge, W.; Lehman, V. HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state. EMBO J 14:546-554; 1995.
81. H. Xiao, C. Neuveut, H.L. Tiffany, M. Benkirane, E.A. Rich, P.M. Murphy, and K. -T. Jeang Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1 Proc Natl Acad Sci USA 97 2000 11466 11471
82. I.E. András, H. Pu, M.A. Deli, A. Nath, B. Hennig, and M. Toborek HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells J Neurosci Res 74 2003 255 265
83. M. Toborek, Y.W. Lee, H. Pu, A. Malecki, G. Flora, R. Garrido, B. Hennig, H.C. Bauer, and A. Nath HIV-Tat protein induced oxidative and inflammatory pathways in brain endothelium J Neurochem 84 2003 169 179
84. T. Price, N. Ercal, R. Nakaoke, and W.A. Banks HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells Brain Res 1045 2005 57 63
85. H. -S. Zhang, H. -Y. Li, Y. Zhou, M. -R. Wu, and H. -S. Zhou Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation Free Radic Biol Med 47 2009 261 268
86. S.R. Opalenik, Q. Ding, S.R. Mallery, and J.A. Thompson Glutathione depletion associated with the HIV-1 TAT protein mediates the extracellular appearance of acidic fibroblast growth factor Arch Biochem Biophys 351 1998 17 26
87. A. Banerjee, X. Zhang, K.R. Manda, W.A. Banks, and N. Ercal HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide Free Radic Biol Med 48 2010 1388 1398
88. M. -J. Richard, P. Guiraud, C. Didier, M. Seve, S.C. Flores, and A. Favier Human immunodeficiency virus type 1 Tat protein impairs selenoglutathione peroxidase expression and activity by a mechanism independent of cellular selenium uptake: consequences on cellular resistance to UV-A radiation Arch Biochem Biophys 386 2001 213 220
89. S.C. Flores, J.C. Marecki, K.P. Harper, S.K. Bose, S.K. Nelson, and J.M. McCord Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells Proc Natl Acad Sci USA 90 1993 7632 7636
90. J.C. Marecki, C. -G.A. Vaitaitis, G.M. Honda, J.R. Porntadivity, S. Clair St, and D.K.S.C. Flores HIV-1 Tat regulates the SOD2 basal promoter by altering Sp1/Sp3 binding activity Free Radic Biol Med 37 2004 869 890
91. Y. Gu, R.F. Wu, Y.C. Xu, S.C. Flores, and L.S. Terada HIV Tat activates c-Jun amino-terminal kinase through an oxidant-dependent mechanism Virology 286 2001 62 71
92. 2 mediates endoplasmic reticulum signaling through local Ras activation Mol Cell Biol 30 2010 3553 3568
93. M. Geyer, O.T. Fackler, and B.M. Peterlin Structure-function relationships in HIV-1 Nef EMBO Rep 2 2001 580 585
94. M. Harris HIV: a new role for Nef in the spread of HIV Curr Biol 9 1999 R463-R463
95. F. Villhardt, O. Plastre, M. Sawada, K. Suzuki, M. Wiznerowicz, E. Kiyokawa, D. Trono, and K.H. Krause The HIV-1 Nef protein and phagocyte NADPH oxidase activation J Biol Chem 277 2002 42136 42143
96. S. Salmen, M. Colmenares, D.L. Peterson, E. Reyes, J.D. Rosales, and L. Berrueta HIV-1 Nef associates with p22-phox, a component of the NADPH oxidase protein complex Cell Immunol 263 2010 166 171
97. P. Duffy, X. Wang, P.H. Lin, Q. Yao, and C. Chen HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells J Surg Res 156 2009 257 264
98. J.C. Marecki, C.D. Cool, J.E. Parr, V.E. Beckey, P.A. Luciw, A.F. Tarantal, A. Carville, R.P. Shannon, A. Cota-Gomez, R.M. Tuder, N.F. Voelkel, and S.C. Flores HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques Am J Respir Crit Care Med 174 2006 437 445
99. P.B. Sehgal, S. Mukhopadhyay, K. Patel, F. Xu, S. Almodóvar, R.M. Tuder, and S.C. Flores Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques Am J Physiol Lung Cell Mol Physiol 297 2009 L729 L737
100. S. Almodovar, P.Y. Hsue, J. Morelli, L. Huang, and S.C. Flores Lung HIV Study. Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 nef Proc Am Thorac Soc 8 2011 308 312
101. E.O. Freed, and M.A. Martin The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection J Biol Chem 270 1995 23883 23886
102. S.K. Oh, C.W. Raina, J. Blanchard, G.C. Adler, W.H. Walker, and J.H. Kornfeld Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients J Acquired Immune Defic Syndr 5 1992 251 256
103. A. Holguin, K.A. O'Connor, J. Biedenkapp, J. Campisi, J. Wieseler-Frank, E.D. Milligan, M.K. Hansen, L. Spataro, E. Maksimova, C. Bravmann, D. Martin, M. Fleshner, S.F. Maier, and L.R. Watkins HIV-1 gp120 stimulates proinflammatory cytokine-mediated pain facilitation via activation of nitric oxide synthase-I (nNOS) Pain 110 2004 517 530
104. G. Bagetta, S. Piccirilli, C. Del Duca, L.A. Morrone, L. Rombola, G. Nappu, J. De Alba, R.G. Knowles, and M.T. Corasaniti Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat Neurosci Lett 235 2004 183 186
105. H. Gendelman, P. Genis, M. Jett, Q.H. Zhai, and H.S. Nottet An experimental model system for HIV-1-induced brain injury Adv Neuroimmunol 4 1994 189 193
106. P.C. Singhal, K. Reddy, N. Franki, and G Ding HIV-1 gp120 envelope protein modulates proliferation of human glomerular epithelial cells J Cell Biochem 76 2000 61 70
107. M. -B. Huang, M. Khan, M. Garcia-Barrio, M. Powell, and V.C. Bond Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120 J Acquired Immune Defic Syndr 27 2001 213 221
108. P. Annunziata, C. Cioni, S. Toneatto, and E. Paccagnini HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P AIDS 12 1998 2377 2385
109. Kanmogne, G. D.; Primeaux, C.; Grammas, P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. J Neuropathol Exp Neurol 64: 498-505; 2005.
110. V. Visalli, C. Muscoli, I. Sacco, F. Sculco, E. Palma, N. Costa, C. Colica, D. Rotiroti, and V. Mollace N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction BMC Neurosci 8 2007 106
111. Q.R. Yu, Z.P. Zhang, H. Zhang, H.T. Lin, X.M. Li, L. Bai, and W.B. Cai Inducible nitric oxide synthase is involved in the oxidation stress induced by HIV-1 gp120 in human retina pigment epithelial cells Chin Med J (Engl) 121 2008 2578 2583
112. J. -P. Louboutin, L. Agrawal, B.A.S. Reyes, E.J. Van Bockstaele, and D.S. Strayer HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress J Neuropathol Exp Neurol 69 2010 801 816
113. D. Pietraforte, E. Tritarelli, U. Testa, and M. Minetti gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages J Leukocyte Biol 55 1994 175 182
114. V. Shatrov, F. Ratter, A. Gruber, W. Droge, and V. Lehmann HIV type 1 glycoprotein amplifies tumor necrosis factor-induced NF-κB activation in Jurkat cells AIDS Res Hum Retroviruses 12 1996 1209 1216
115. I.O. Foga, A. Nath, B.B. Hasinoff, and J.D. Geiger Antioxidants and dipyridamole inhibit HIV-1 gp120-induced free radical-based oxidative damage to human monocytoid cells J Acquired Immune Defic Syndr Hum Retrovirol 16 1997 223 229
116. X. Fan, P.C. Joshi, M. Koval, and D.M. Guidot Chronic alcohol ingestion exacerbates lung epithelial barrier dysfunction in HIV-1 transgenic rats Alcohol Clin Exp Res 35 2011 1866 1875
117. E.A. Cohen, G. Dehni, J.G. Sodroski, and W.A. Haseltine Human immunodeficiency virus vpr product is a virion-associated regulatory protein J Virol 64 1990 3097 3099
118. M. Kogan, and J Rappaport HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention Retrovirology 8 2011 25
119. D. Levy, Y. Refaeli, and D. Weiner Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency J Virol 69 1995 1243 1252
120. D.N. Levy, Y. Refaeli, R.R. MacGregor, and D.B. Weiner Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1 Proc Natl Acad Sci USA 91 1994 10873 10877
121. S. Hoshino, B. Sun, M. Konishi, M. Shimura, T. Segawa, Y. Hagiwara, Y. Koyanagi, A. Iwamoto, J. -I. Mimaya, H. Terunuma, S. Kano, and Y. Ishizaka Vpr in plasma of HIV type 1-positive patients is correlated with the HIV Type 1 RNA titers AIDS Res Hum Retroviruses 23 2007 391 397
122. S.L. Deshmane, R. Mukerjee, S. Fan, L. Del Valle, C. Michiels, T. Sweet, I. Rom, K. Khalili, J. Rappaport, S. Amini, and B.E. Sawaya Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1α expression J Biol Chem 284 2009 11364 11373
123. S. Hoshino, M. Konishi, M. Mori, M. Shimura, C. Nishitani, Y. Kuroki, Y. Koyanagi, S. Kano, H. Itabe, and Y Ishizaka HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency J Leukocyte Biol 87 2010 1133 1143
124. E.R. Kline, and R.L. Sutliff The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction J Invest Med 56 2008 752 769
125. M. Pinti, P. Salomoni, and A. Cossarizza Anti-HIV drugs and the mitochondria Biochim Biophys Acta Bioenerg 700-707 1757 2006
126. T. Hulgan, J. Morrow, R.T. DAquila, S. Raffanti, M. Morgan, P. Rebeiro, and D.W. Haas Oxidant stress is increased during treatment of human immunodeficiency virus infection Clin Infect Dis 37 2003 1711 1717
127. Gil, L.; Tarinas, A.; Hernández, D.; Riverón, B. V.; Pérez, D.; Tápanes, R.; Capo, V.; Pérez, J. Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy. Biomed Pharmacother, 10.1016/j.biopha.2010.09.009, in press.
128. M. Sundaram, S. Saghayam, B. Priya, K.K. Venkatesh, P. Balakrishnan, E.M. Shankar, K.G. Murugavel, S. Solomon, and N. Kumarasamy Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India Int J Infect Dis 12 2008 e61-e66
129. E.R. Pacht, P. Diaz, T. Clanton, J. Hart, and J.E. Gadek Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time Chest 112 1997 785 788
130. R.L. Sutliff, S. Dikalov, D. Weiss, J. Parker, S. Raidel, A.K. Racine, R. Russ, C.P. Haase, W.R. Taylor, and W. Lewis Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide Am J Physiol Heart Circ Physiol 283 2002 H2363 H2370
131. E. Kline, L. Bassit, B. Hernandez-Santiago, M. Detorio, B. Liang, D. Kleinhenz, E. Walp, S. Dikalov, D. Jones, R. Schinazi, and R. Sutliff Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction Cardiovasc Toxicol 9 2009 1 12
132. B. Jiang, A.R. Khandelwal, L.K. Rogers, V.Y. Hebert, J.J. Kleinedler, J.H. Zavecz, W. Shi, A.W. Orr, and T.R. Dugas Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia Toxicol Sci 117 2010 524 536
133. I. Papparella, G. Ceolotto, L. Berto, M. Cavalli, S. Bova, G. Cargnelli, E. Ruga, O. Milanesi, L. Franco, M. Mazzoni, L. Petrelli, G.G. Nussdorfer, and A. Semplicini Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat Cardiovasc Res 73 2007 432 438
134. T. Yamaguchi, I. Katoh, and S. -I. Kurata Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization Eur J Biochem 269 2002 2782 2788
135. W. Lewis Defective mitochondrial DNA replication and NRTIs: pathophysiological implications in AIDS cardiomyopathy Am J Physiol Heart Circ Physiol 284 2003 H1 9
136. J. Pupure, M.A.S. Fernandes, M.S. Santos, A.J.M. Moreno, I. Kalvinsh, V. Klusa, and C.R. Oliveira Mitochondria as the target for mildronates protective effects in azidothymidine (AZT)-induced toxicity of isolated rat liver mitochondria Cell Biochem Funct 26 2008 620 631
137. R.Y. Gao, M.P. Mohanraj, R. Wang, H. Horvath, B. Yin, and S.P. Pacher Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes Mol Med Rep 4 2011 151 155
138. M. Caron, M. Auclairt, A. Vissian, C. Vigouroux, and J. Capeau Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues Antiviral Ther 13 2008 27 38
139. W.O. Opii, V.N. Nukala, R. Sultana, J.D. Pandya, K.M. Day, M.L. Merchant, J.B. Klein, P.G. Sullivan, and D.A. Butterfield Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury J Neurotrauma 24 2007 772 789
140. J.J. Kohler, I. Cucoranu, E. Fields, E. Green, S. He, A. Hoying, R. Russ, A. Abuin, D. Johnson, S.H. Hosseini, C.M. Raper, and W. Lewis Transgenic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy Lab Invest 89 2009 782 790
141. K.C. Lund, and K.B. Wallace Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors Toxicol Appl Pharmacol 226 2008 94 106
142. A.M. Komarov, J.M. Hall, and W.B. Weglicki Azidothymidine promotes free radical generation by activated macrophages and hydrogen peroxide-iron-mediated oxidation in a cell-free system Biochim Biophys Acta Mol Basis Dis 257-264 1688 2004
143. I.T. Mak, and N.L.W.B. Weglicki Pro-oxidant properties and cytotoxicity of AZT-monophosphate and AZT Cardiovasc Toxicol 4 2004 109 115
144. D.C. Erik The role of non-nucleoside reverse transcriptase inhibitors
145. J. Adams, N. Patel, N. Mankaryous, M. Tadros, and C.D. Miller Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents Ann Pharmacother 44 2010 157 165
146. S.S. Shankar, M.P. Dubé, J.C. Gorski, J.E. Klaunig, and H.O. Steinberg Indinavir impairs endothelial function in healthy HIV-negative men Am Heart J 150 2005 933 937
147. C. Chen, X. -H. Lu, S. Yan, H. Chai, and Q. Yao HIV protease inhibitor ritonavir increases endothelial monolayer permeability Biochem Biophys Res Commun 335 2005 874 882
148. R. Ben-Romano, R.A. Etzion, S. Potashnik, R. Kagan, E. Greenbaum, and U.N. Bashan Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents Antiviral Ther 11 2006 1051 1060
149. S.P. Vincent, F. Tourniaire, C.M. El Yazidi, E. Compe, O. Manches, R. Plannels, and R.G. Roche Nelfinavir induces necrosis of 3T3F44-2A adipocytes by oxidative stress J Acquired Immune Defic Syndr 37 2004 1556 1562
150. C.E.B. Lagathu, M. Prot, D. Frantz, Y. Gu, J.P. Bastard, M. Maachi, S. Azoulav, M. Briggs, M. Caron, and J. Capeau Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages Antiviral Ther 12 2007 489 500
151. D. Mondal, L. Pradhan, M. Ali, and K.C. Agrawal HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants Cardiovasc Toxicol 4 2004 287 302
152. C. Lefévre, M. Auclair, F. Boccara, J. -P. Bastard, J. Capeau, C. Vigouroux, and M. Caron-Debarle Premature senescence of vascular cells is induced by HIV protease inhibitors Arterioscler Thromb Vasc Biol 30 2010 2611 2620
153. S. Chandra, D. Mondal, and K.C. Agrawal HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone Exp Biol Med 234 2009 442 453
154. X. Wang, H. Mu, H. Chai, D. Liao, Q. Yao, and C. Chen Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells Am J Pathol 171 2007 304 314
155. H. Chai, H. Yang, S. Yan, M. Li, P.H. Lin, A.B. Lumsden, Q. Yao, and C. Chen Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries J Acquired Immune Defic Syndr 40 2005 12 19
156. H. Chai, S. Yan, P. Lin, A.B. Lumsden, Q. Yao, and C. Chen Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries J Am Coll Surg 200 2005 820 830
157. H. Chai, W. Zhou, P. Lin, A. Lumsden, Q. Yao, and C. Chen Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries Am J Physiol Heart Circ Physiol 288 2005 H2965 H2971
158. K.R. Manda, A. Banerjee, W.A. Banks, and N. Ercal Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells Free Radic Biol Med 50 2011 801 810
159. F.J. Giordano Oxygen, oxidative stress, hypoxia, and heart failure J Clin Invest 115 2005 500 508
160. T. Kondo, M. Hirose, and K. Kageyama Roles of oxidative stress and redox regulation in atherosclerosis J Atheroscler Thromb 16 2009 532 538
161. Y. -M. Go, and D.P. Jones Cysteine/cystine redox signaling in cardiovascular disease Free Radic Biol Med 50 2011 495 509
162. C.A. Papaharalambus, and K.K. Griendling Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury Trends Cardiovasc Med 17 2007 48 54
163. J. Nordberg, and E.S.J. Arnér Reactive oxygen species, antioxidants, and the mammalian thioredoxin system Free Radic Biol Med 31 2001 1287 1312
164. K. Irani Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling Circ Res 87 2000 179 183
165. K.K. Griendling, D. Sorescu, B. Lassègue, and M. Ushio-Fukai Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology Arterioscler Thromb Vasc Biol 20 2000 2175 2183
166. M. Ushio-Fukai Compartmentalization of redox signaling through NADPH oxidase-derived ROS Antioxid Redox Signaling 11 2009 1289 1299
167. T.G. Canty, E.M. Boyle, A. Farr, E.N. Morgan, E.D. Verrier, and T.H. Pohlman Oxidative stress induces NF-κB nuclear translocation without degradation of IκBα Circulation 100 1999 II-361-II-364
168. B.S. Wung, J.J. Cheng, H.J. Hsieh, Y.J. Shyy, and D.L. Wang Cyclic strain-induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1 Circ Res 81 1997 1 7
169. T.L. Wellman, J. Jenkins, P.L. Penar, B. Tranmer, R. Zahr, and K.M. Lounsbury Nitric oxide and reactive oxygen species exert opposing effects on the stability of hypoxia inducible factor-1α (HIF-1α) in explants of human pial arteries FASEB J 18 2004 379 381
170. - in vascular smooth muscle cells Circ Res 77 1995 29 36
171. Z. Xia, M. Liu, Y. Wu, V. Sharma, T. Luo, J. Ouyang, and J.H. McNeill N-acetylcysteine attenuates TNF-α-induced human vascular endothelial cell apoptosis and restores eNOS expression Eur J Pharmacol 550 2006 134 142
172. M. Luchtefeld, K. Grote, C. Grothusen, S. Bley, N. Bandlow, T. Selle, M. Strüber, A. Haverich, U. Bavendiek, H. Drexler, and B. Schieffer Angiotensin II induces MMP-2 in a p47phox-dependent manner Biochem Biophys Res Commun 328 2005 183 188
173. J. Bauersachs, R. Popp, M. Hecker, E. Sauer, I. Fleming, and R. Busse Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor Circulation 94 1996 3341 3347
174. N. Kuzkaya, N. Weissmann, D.G. Harrison, and S. Dikalov Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols J Biol Chem 278 2003 22546 22554
175. J.A. Suwaidi, S. Hamasaki, S.T. Higano, R.A. Nishimura, D.R. Holmes, and A. Lerman Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction Circulation 101 2000 948 954
176. V.Z.A. Schachinger Atherosclerosis-associated endothelial dysfunction Z Kardiol 89 Suppl. 9 2000 70 74
177. N. Gokce, J.F. Keaney, L.M. Hunter, M.T. Watkins, Z.S. Nedeljkovic, J.O. Menzoian, and J.A. Vita Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease J Am Coll Cardiol 41 2003 1769 1775
178. L.A. Brennan, R.H. Steinhorn, S. Wedgwood, E. Mata-Greenwood, E.A. Roark, J.A. Russell, and S.M. Black Increased superoxide generation is associated with pulmonary hypertension in fetal lambs Circ Res 92 2003 683 691
179. R. Bowers, C. Cool, R.C. Murphy, R.M. Tuder, M.W. Hopken, S.C. Flores, and N.F. Voelkel Oxidative stress in severe pulmonary hypertension Am J Respir Crit Care Med 169 2004 764 769
180. F.T. Kaneko, A.C. Arroliga, R.A. Dweik, S.A. Comhair, D. Laskowski, R. Oppedisano, M.J. Thomassen, and S.C. Erzurum Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension Am J Respir Crit Care Med 158 1998 917 923
181. R.F. Machado, M.V. Londhe Nerkar, R.A. Dweik, J. Hammel, A. Janocha, J. Pyle, D. Laskowski, C. Jennings, A.C. Arroloiga, and S.C. Erzurum Nitric oxide and pulmonary arterial pressures in pulmonary hypertension Free Radic Biol Med 37 2004 1010 1017
182. H. Cai, and D.G. Harrison Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress Circ Res 87 2000 840 844
183. J.Q. Liu, I.N. Zelko, and R.J. Folz Reoxygenation-induced constriction in murine coronary arteries J Biol Chem 279 2004 24493 24497
184. S. Wedgwood, and S.M. Black Induction of apoptosis in fetal pulmonary arterial smooth muscle cells by a combined superoxide dismutase/catalase mimetic Am J Physiol Lung Cell Mol Physiol 285 2003 L305 L312
185. K. Szöcs, B. Lassègue, D. Sorescu, L.L. Hilenski, L. Valppu, T.L. Couse, J.N. Wilcox, M.T. Quinn, K.K. Griendling, and J.D. Lambeth Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury Arterioscler Thromb Vasc Biol 22 2002 21 27
186. T.J. Guzik, J. Sadowski, B. Guzik, A. Jopek, B. Kapelak, P. Przybylowski, K. Wierzbicki, R. Korbut, D.G. Harrison, and K.M. Channon Coronary artery superoxide production and Nox isoform expression in human coronary artery disease Arterioscler Thromb Vasc Biol 26 2006 333 339
187. D. Sorescu, D. Weiss, B. Lassègue, R.E. Clempus, K. Szöcs, G.P. Sorescu, L. Valppu, M.T. Quinn, J.D. Lambeth, J.D. Vega, W.R. Taylor, and K.K. Griendling Superoxide production and expression of Nox family proteins in human atherosclerosis Circulation 105 2002 1429 1435
188. A.E. Vendrov, Z.S. Hakim, N.R. Madamanchi, M. Rojas, C. Madamanchi, and M.S. Runge Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells Arterioscler Thromb Vasc Biol 27 2007 2714 2721
189. N. Marui, O.M. Swerlick, R. Kunsch, C. Rosen, C.A. Ahmad, M. Alexander, and R.M. Medford Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells J Clin Invest 92 1993 1866 1874
190. H. Takatsu, H. Tasaki, H.-N. Kim, S. Ueda, M. Tsutsui, K. Yamashita, T. Toyokawa, Y. Morimoto, Y. Nakashima, and T. Adachi Overexpression of EC-SOD suppresses endothelial-cell-mediated LDL oxidation Biochem Biophys Res Commun 285 2001 84 91
191. L. Cominacini, U. Garbin, A.F. Pasini, A. Davoli, M. Campagnola, G.B. Contessi, A.M. Pastorino, and V. Lo Cascio Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells Free Radic Biol Med 22 1997 117 127
192. B.S. Wung, J.J. Cheng, S. -K. Shyue, and D.L. Wang NO modulates monocyte chemotactic protein-1 expression in endothelial cells under cyclic strain Arterioscler Thromb Vasc Biol 21 2001 1941 1947
193. 2, and iron are required for TNF-α-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase Am J Physiol Heart Circ Physiol 286 2004 H1001 H1007
194. S. Devaraj, D. Li, and I. Jialal The effects of α tocopherol supplementation on monocyte function: decreased lipid oxidation, interleukin 1β secretion, and monocyte adhesion to endothelium J Clin Invest 98 1996 756 763
195. A. Lerman, B.S. Edwards, J.W. Hallett, D.M. Heublein, S.M. Sandberg, and J.C. Burnett Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis N Engl J Med 325 1991 997 1001
196. A.M. Zeiher, H. Goebel, V. Schächinger, and C. Ihling Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina Circulation 91 1995 941 947
197. L. Savale, L. Tu, D. Rideau, M. Izziki, B. Maitre, S. Adnot, and S. Eddahibi Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice Respir Res 10 2009 6
198. M.K. Steiner, O.L. Syrkina, N. Kolliputi, E.J. Mark, C.A. Hales, and A.B. Waxman Interleukin-6 overexpression induces pulmonary hypertension Circ Res 104 2009 236 244
199. S.M. Golembeski, J. West, Y. Tada, and K.A. Fagan Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice Chest 128 2005 572S 573S
200. J.R. Michael, B.A. Markewitz, and D.E. Kohan Oxidant stress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells Am J Physiol Lung Cell Mol Physiol 273 1997 L768 L774
201. A.S. Sethi, D.M. Lees, J.A. Douthwaite, A.B. Dawnay, and R. Corder Homocysteine-induced endothelin-1 release is dependent on hyperglycaemia and reactive oxygen species production in bovine aortic endothelial cells J Vasc Res 43 2006 175 183
202. F. Syeda, E. Tullis, A.S. Slutsky, and H. Zhang Human neutrophil peptides upregulate expression of COX-2 and endothelin-1 by inducing oxidative stress Am J Physiol Heart Circ Physiol 294 2008 H2769 H2774
203. J. Turchan-Cholewo, V.M. Dimayuga, S. Gupta, R.M.C. Gorospe, J.N. Keller, and A.J. Bruce-Keller NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat Antioxid Redox Signaling 11 2008 193 204
204. F. Böhm, M. Settergren, and J. Pernow Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo Atherosclerosis 190 2007 408 415
205. M. Browatzki, J. Schmidt, W. Kübler, and R. Kranzhöfer Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-κB in human vascular smooth muscle cells Basic Res Cardiol 95 2000 98 105
206. D.L. Pitrak, K.M. Mullane, M.L. Bilek, P. Stevens, and R.C. Allen Impaired phagocyte oxidative capacity in patients with human immunodeficiency virus infection J Lab Clin Med 132 1998 284 293
207. H. Koziel, X. Li, M.Y.K. Armstrong, F.F. Richards, and R.M. Rose Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro Am J Respir Cell Mol Biol 23 2000 452 459
208. G.W. Pace, and C.D. Leaf The role of oxidative stress in HIV disease Free Radic Biol Med 19 1995 523 528
209. S. Kurata Sensitization of the HIV-1-LTR upon long term low dose oxidative stress J Biol Chem 271 1996 21798 21802
210. G.M.B.R. Adamson Tumor necrosis factor induced oxidative stress in isolated mouse hepatocytes Arch Biochem Biophys 294 1992 223 229
211. F.J. Staal, M. Roederer, and L.A. Herzenberg Intracellular thiols regulate activation of nuclear factor κB and transcription of human immunodeficiency virus Proc Natl Acad Sci USA 87 1990 9943 9947
212. S. Mihm, J. Ennen, U, Pessara, R, Kurth, and W. Droge Inhibition of HIV-1 replication and NF-κB activity by cysteine and cysteine derivatives AIDS 5 1991 497 503
213. E. Vicenzi, and G. Poli Regulation of HIV expression by viral genes and cytokines J Leukocyte Biol 56 1994 328 334
214. R.R.P. Schreck, and P.A. Baeuerle Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1 EMBO J 10 1991 2247 2258
215. M. Roederer, P.A. Raju, F.J. Staal, L.A. Herzenberg, and L.A. Herzenberg N-acetylcysteine inhibits HIV expression in chronically infected cells AIDS Res Hum Retroviruses 7 1991 563 567
216. F.J. Staal, M.T. Anderson, and L.A. Herzenberg Redox regulation of NF-κB transcription factor complex: effects of N-acetylcysteine Methods Enzymol 252 1995 168 174
217. F.J. Staal, M. Roederer, P.A. Raju, M.T. Anderson, S.W. Ela, and L.A. Herzenberg Antioxidants inhibit stimulation of HIV transcription AIDS Res Hum Retroviruses 9 1993 299 306
218. T. Kalebic, A. Kinter, G. Poli, M.E. Anderson, A. Meister, and A.S. Fauci Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine Proc Natl Acad Sci USA 88 1991 986 990
219. E. Garaci, A.T. Palamara, M.R. Ciriolo, C. D'Agostini, M.S. Abdel-Latif, S. Aquaro, E. Lafavia, and G. Rotilio Intracellular GSH content and HIV replication in human macrophages J Leukocyte Biol 62 1997 54 59
220. A.T. Palamara, C.F. Perno, S. Aquaro, M.C. Bue, L. Dini, and E. Garaci Glutathione inhibits HIV replication by acting at late stages of the virus life cycle AIDS Res Hum Retroviruses 12 1996 1537 1541
221. J. Oiry, P. Mialocq, J.Y. Puy, P. Fretier, N. Dereuddre-Bosquet, D. Dormont, J.L. Imbach, and P. Clayette Synthesis and biological evaluation in human monocyte-derived macrophages of N-(N-acetyl-l-cysteinyl)-S- acetylcysteamine analogues with potent antioxidant and anti-HIV activities J Med Chem 47 2004 1789 1795
222. W. Ho, and S.D. Douglas Glutathione and N-acetylcysteine suppression of human immunodeficiency virus replication in human monocytes/macrophages in vitro AIDS Res Hum Retroviruses 8 1992 1249 1253
223. M. Magnani, A. Fraternale, A. Casabianca, G.F. Schiavano, L. Chiarantini, A.T. Palamara, M.R. Ciriolo, G. Rotilio, and E. Garaci Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AID AIDS Res Hum Retroviruses 13 1997 1093 1099
224. A.T. Palamara, E. Garaci, G. Rotilio, M.R. Ciriolo, A. Casabianca, A. Fraternale, L. Rossi, G.F. Schiavano, L. Chiarantini, and M. Magnani Inhibition of murine AIDS by reduced glutathione AIDS Res Hum Retroviruses 12 1996 1373 1381
225. A. Fraternale, A. Casabianca, C. Orlandi, A. Cerasi, L. Chiarantini, G. Brandi, and M. Magnani Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model Antiviral Res 56 2002 263 272
226. N.B. Siddappa, M. Venkatramanan, P. Venkatesh, M.V. Janki, N. Jayasuryan, A. Desai, V. Ravi, and U. Ranga Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein Retrovirology 3 2006 53
227. R. Pierleoni, M. Menotta, A. Antonelli, C. Sfara, G. Serafini, S. Dominici, M.E. Laguardia, A. Salis, G. Damonte, L. Banci, M. Porcu, P. Monini, B. Ensoli, and M. Magnani Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking Mol Cell Biochem 345 2010 105 118
228. E. Fanales-Belasio, S. Moretti, F. Nappi, G. Barillari, F. Micheletti, A. Cafaro, and B. Ensoli Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses J Immunol 168 2002 197 206
229. P. Kalantari, V. Narayan, S.K. Natarajan, K. Muralidhar, U.H. Gandhi, H. Vunta, A.J. Henderson, and K.S. Prabhu Thioredoxin reductase-1 negatively regulates HIV-1 transactivating protein Tat-dependent transcription in human macrophages J Biol Chem 283 2008 33183 33190
230. V. Appay, and D. Sauce Immune activation and inflammation in HIV-1 infection: causes and consequences J Pathol 214 2008 231 241
231. Y. Kerttula, M. Vaara, L. Pyhala, H. Sariola, E. Kostiainen, and J.K. Huttunen Effect of bacterial lipopolysaccharide on serum lipids and on the development of aortic atherosclerosis in rabbits Atherosclerosis 59 1986 307 312
232. M.A. Ostos, D. Recalde, M.M. Zakin, and D. Scott-Algara Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation FEBS Lett 519 2002 23 29
233. W.K. den Dekker, C. Cheng, G. Pasterkamp, and H.J. Duckers Toll like receptor 4 in atherosclerosis and plaque destabilization Atherosclerosis 209 2010 314 320
234. K.C. Young, S.M.A. Hussein, R. Dadiz, D. deMello, C. Devia, D. Hehre, and C. Suguihara Toll-like receptor 4-deficient mice are resistant to chronic hypoxia-induced pulmonary hypertension Exp Lung Res 36 2010 111 119
235. H. Kirii, T. Niwa, Y. Yamada, H. Wada, K. Saito, Y. Iwakura, M. Asano, H. Moriwaki, and M. Seishima Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice Arterioscler Thromb Vasc Biol 23 2003 656 660
236. J.H. Lim, H.J. Um, J.W. Park, I.K. Lee, and T.K. Kwon Interleukin-1β promotes the expression of monocyte chemoattractant protein-1 in human aorta smooth muscle cells via multiple signaling pathways Exp Mol Pathol 41 2009 757 764
237. N. Takeda, I. Manabe, T. Shindo, H. Iwata, S. Iimuro, H. Kagechika, K. Shudo, and R. Nagai Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6 Arterioscler Thromb Vasc Biol 26 2006 1177 1183
238. A. Saremi, R.J. Anderson, P. Luo, T.E. Moritz, D.C. Schwenke, M. Allison, and P.D. Reaven Association between IL-6 and the extent of coronary atherosclerosis in the Veterans Affairs Diabetes Trial (VADT) Atherosclerosis 203 2009 610 614
239. M. Humbert, G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grandeot-Keros, P. Duroux, P. Galanaud, G. Simonneau, and D. Emilie Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension Am J Respir Crit Care Med 151 1995 1628 1631
240. A. Bhargava, A. Kumar, N. Yuan, M.H. Gewitz, and R. Mathew Monocrotaline induced interleukin-6 mRNA expression in rat lungs Heart Dis 1 1999 126 132
241. M. Hagen, K. Fagan, W. Steudel, M. Carr, K. Lane, D.M. Rodman, and J. West Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle Am J Physiol Lung Cell Mol Physiol 292 2007 L1473 L1479
242. A. Marandin, A. Katz, E. Oksenhendler, M. Tulliez, F. Picard, W. Vainchenker, and F. Louache Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection Blood 88 1996 4568 4578
243. M. Jenkins, M.B. Hanley, M.B. Moreno, E. Wieder, and J.M. McCune Human immunodeficiency virus-1 infection interrupts thymopoiesis and multilineage hematopoiesis in vivo Blood 91 1998 2672 2678
244. A.V. Moses, J.A. Nelson, and G.C. Bagby The influence of human immunodeficiency virus-1 on hematopoiesis Blood 91 1998 1479 1495
245. Y.D. Zhao, D.W. Courtman, Y. Deng, L. Kugathasan, Q. Zhang, and D.J. Stewart Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells Circ Res 96 2005 442 450
246. M.L. Ormiston, Y. Deng, D.J. Stewart, and D.W. Courtman Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension Am J Respir Cell Mol Biol 43 2010 546 554
247. L. Taraseviciene-Stewart, M.R. Nicolls, D. Kraskauskas, R. Scerbavicius, N. Burns, C. Cool, K. Wood, J.E. Parr, S.A. Boackle, and N.F. Voelkel Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling Am J Respir Crit Care Med 175 2007 1280 1289
248. E.D. Austin, M.T. Rock, C.A. Mosse, C.L. Vnencak-Jones, S.M. Yoder, I.M. Robbins, J.E. Loyd, and B.O. Meyrick T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension Respir Med 104 2010 454 462
249. D. Kolbus, O. Ramos, K. Berg, J. Persson, M. Wigren, H. Bjorkbacka, G. Fredrikson, and J. Nilsson CD8 T cell activation predominate early immune responses to hypercholesterolemia in ApoE-/-mice BMC Immunol 11 2010 58
250. Y. Kamide, M. Utsugi, K. Dobashi, A. Ono, T. Ishizuka, T. Hisada, Y. Koga, K. Uno, J. Hamuro, and M. Mori Intracellular glutathione redox status in human dendritic cells regulates IL-27 production and T-cell polarization Allergy 66 2011 1183 1192
251. J.D. Peterson, L.A. Herzenberg, K. Vasquez, and C. Waltenbaugh Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns Proc Natl Acad Sci USA 95 1998 3071 3076
252. S. Romagnani Lymphokine production by human T cells in disease states Annu Rev Immunol 12 1994 227 257
253. J.C.H.D. McArthur, H. Bacellat, E.N. Miller, B.A. Cohen, J.T. Becker, N.M. Graham, J.H. McArthur, O.A. Selnes, and L.P. Jacobson Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS cohort study Neurology 43 1993 2245 2253
254. L. Desquilbet, J.L. Fried, L.P. Phair, J.P. Jamieson, B.D. Holloway, and M.J.B. Margolick Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty J Gerontol A Biol Med Sci 62 2007 1279 1286
255. B.E. Hurwitz, N.G. Klimas, M.M. Llabre, K.J. Maher, J.S. Skyler, M.S. Bilsker, S. McPherson-Baker, P.J. Lawrence, A.R. Laperriere, J.M. Greeson, J.R. Klaus, R. Lawrence, and N. Schneiderman HIV metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: role of protease inhibitor exposure Cardiovasc Toxicol 4 2004 303 316
256. B. Halliwell Antioxidant defence mechanisms: from beginning to the end (of the beginning) Free Radic Res 31 1999 261 272
257. C.B. Stephenson, G.S. Marquis, R.A. Jacob, L.A. Kruzich, S.D. Douglas, and C.M. Wilson Vitamins C and E in adolescents and young adults with HIV infection Am J Clin Nutr 83 2006 870 879
258. L.A. Kruzich, G.S. Marquis, A.L. Carriquiry, C.M. Wilson, and C.B. Stephensen US youths in the early stages of HIV disease have low intakes of some micronutrients important for optimal immune function J Am Diet Assoc 104 2004 1095 1101
259. A.M. Tang, N.M. Graham, A.J. Kirby, L.D. McCall, W.C. Willet, and A.J. Saah Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men Am J Epidemiol 138 1993 937 951
260. A.M. Tang, N.M.H. Graham, R.D. Semba, and A.J. Saah Association between serum vitamin A and E levels and HIV-1 disease progression AIDS 11 1997 613 620
261. W.W. Fawzi, G.I. Msamanga, D. Spiegelman, R. Wei, S. Kapiga, E. Villamor, D. Mwakagile, F. Mugusi, E. Hertzmark, M. Essex, and D.J.A Hunter randomized trial of multivitamin supplements and HIV disease progression and mortality N Engl J Med 351 2004 23 32
262. R.S. McClelland, J.M. Baeten, J. Overbaugh, B.A. Richardson, K. Mandaliya, S. Emery, L. Lavreys, J.O. Ndinya-Achola, D.D. Bankson, J.J. Bwayo, and J.K. Kreiss Micronutrient supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial J Acquired Immune Defic Syndr 37 2004 1657 1663
263. J.P. Allard, E. Aghdassi, J. Chau, C. Tam, C.M. Kovacs, I.E. Salit, and S.L. Walmsley Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects AIDS 12 1998 1653 1659
264. Spada, C.; Treitinger, A. C.; Reis, M.; Masokawa, I. Y.; Verdi, J. L. C.; Luiz, M. C.; Silveira, M. V. S.; Oliveira, O. V.; Michelon, C. M.; Avila-Junior, S. L.; Gil, I. D. O.; Ostrowsky, S. An evaluation of antiretroviral therapy associated with α-tocopherol supplementation in HIV-infected patients. Clin Chem. Lab Med 40: 456-459; 2002.
265. R. Kupka, F. Mugusi, S. Aboud, G.I. Msamanga, J.L. Finkelstein, D. Spiegelman, and W.W. Fawzi Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes Am J Clin Nutr 87 2008 1802 1808
266. B.E. Hurwitz, J.R. Klaus, M.M. Llabre, A. Gonzalez, P.J. Lawrence, K.J. Maher, J.M. Greeson, M.K. Baum, G. Shor-Posner, J.S. Skyler, and N. Schneiderman Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial Arch Intern Med 167 2007 148 154
267. R.J. Jariwalla, J. Lalezari, D. Cenko, S.E. Mansour, A. Kumar, B. Gangapurkar, and D. Nakamura Restoration of blood total glutathione status and lymphocyte function following α-lipoic acid supplementation in patients with HIV infection J Alternat Complement Med 14 2008 139 146
268. J.W. Kaspar, S.K. Niture, and A.K. Jaiswal Nrf2:INrf2 (Keap1) signaling in oxidative stress Free Radic Biol Med 47 2009 1304 1309
269. Z. Ungvari, Z. Bagi, A. Feher, F.A. Recchia, W.E. Sonntag, K. Pearson, R. de Cabo, and A. Csiszar Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2 Am J Physiol Heart Circ Physiol 299 2010 H18 24
270. J.S. Chen, P.H. Huang, C.H. Wang, F.Y. Lin, H.Y. Tsai, T.C. Wu, S.J. Lin, and J.W. Chen Nrf-2 mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to anti-atherogenesis and vascular protective effects of Ginkgo biloba extract Atherosclerosis 214 2011 301 309
271. M. Zakkar, K. Van der Heiden, A. Luong le, H. Chaudhury, S. Cuhlmann, S.S. Hamdulay, R. Krams, I. Edirisinghe, I. Rahman, H. Carlsen, D.O. Haskard, J.C. Mason, and P.C. Evans Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state Arterioscler Thromb Vasc Biol 29:1851-1857 2009
272. X.L. Chen, G. Dodd, S. Thomas, X. Zhang, M.A. Wasserman, B.H. Rovin, and C. Kunsch Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression Am J Physiol Heart Circ Physiol 290 2006 H1862 1870
273. A.L. Levonen, M. Inkala, T. Heikura, S. Jauhiainen, H.K. Jyrkkanen, E. Kansanen, K. Maatta, E. Romppanen, P. Turunen, J. Rutanen, and S. Yla-Herttuala Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo Arterioscler Thromb Vasc Biol 27 2007 741 747
274. T.E. Sussan, J. Jun, R. Thimmulappa, D. Bedja, M. Antero, K.L. Gabrielson, V.Y. Polotsky, and S. Biswal Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice PLoS One 3 2008 e3791
275. T. Ichikawa, J. Li, C.J. Meyer, J.S. Janicki, M. Hannink, and T. Cui Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes PLoS One 4 2009 e8391
276. T.E. Sussan, T. Rangasamy, D.J. Blake, D. Malhotra, H. El-Haddad, D. Bedja, M.S. Yates, P. Kombairaju, M. Yamamoto, K.T. Liby, M.B. Sporn, K.L. Gabrielson, H.C. Champion, R.M. Tuder, T.W. Kensler, and S. Biswal Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice Proc Natl Acad Sci USA 106 2009 250 255
277. E.M. Redout, A. van der Toorn, M.J. Zuidwijk, C.W.A. van de Kolk, C.J.A. van Echteld, R.J.P. Musters, C. van Hardeveld, W.J. Paulus, and W.S Simonides Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure Am J Physiol Heart Circ Physiol 298 2010 H1038 H1047
278. V. Lachmanová, O. Hnilicková, V. Povýsilová, V. Hampl, and J. Herget N-acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia Life Sci 77 2005 175 182
279. C. Antoniades, D. Tousoulis, C. Tentolouris, P. Toutouzas, and C. Stefanadis Oxidative stress, antioxidant vitamins, and atherosclerosis Herz 28 2003 628 638
280. F. Violi, F. Micheletta, and L. Juliano Antioxidants and atherosclerosis Eur Heart J Suppl 4 Suppl. B 2004 B17 B21
281. D.P. Jones Redefining oxidative stress Antioxid Redox Signaling 8 2006 1865 1879
282. J.M. Hansen, Y. -M. Go, and D.P. Jones Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling Annu Rev Pharmacol Toxicol 46 2006 215 234
283. Y. -M. Go, and D.P. Jones Intracellular proatherogenic events and cell adhesion modulated by extracellular thiol/disulfide redox state Circulation 111 2005 2973 2980
284. S. Jiang, S.E. Moriarty-Craige, M. Orr, J. Cai, P. Sternberg, and D.P. Jones Oxidant-induced apoptosis in human retinal pigment epithelial cells: dependence on extracellular redox state Invest Ophthalmol Visual Sci 46 2005 1054 1061
285. I.G.S. Isseman Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
286. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells Arterioscler Thromb Vasc Biol 23 2003 52 57
287. J. Hwang, D.J. Kleinhenz, B. Lassègue, K.K. Griendling, S. Dikalov, and C.M. Hart Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production Am J Physiol Cell Physiol 288 2005 C899 C905
288. J.M. Kleinhenz, D.J. Kleinhenz, S. You, J.D. Ritzenthaler, J.M. Hansen, D.R. Archer, R.L. Sutliff, and C.M. Hart Disruption of endothelial peroxisome proliferator-activated receptor-γ reduces vascular nitric oxide production Am J Physiol Heart Circ Physiol 297 2009 H1647 H1654
289. W. Huang, S.Y. Eum, I.E. András, B. Hennig, and M. Toborek PPARα and PPARγ attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities FASEB J 23 2009 1596 1606
290. S.H. Ramirez, D. Heilman, B. Morsey, R. Potula, J. Haorah, and Y. Persidsky Activation of peroxisome proliferator-activated receptor γ (PPARγ) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes J Immunol 180 2008 1854 1865
291. Y. Ji, J. Liu, Z. Wang, and Z. Li PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway Cytokine 5 2011 409 419
292. S. Kurebayashi, X. Xu, S. Ishii, M. Shiraishi, H. Kouhara, and S. Kasayama A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-α-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells Atherosclerosis 182 2005 71 77
293. O. Prakash, S. Teng, M. Ali, X. Zhu, R. Coleman, R.A. Dabdoub, R. Chambers, T.Y. Aw, S.C. Flores, and B.H. Joshi The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice Arch Biochem Biophys 343 1997 173 180
294. E. Olivetta, D. Pietraforte, I. Schiavoni, M. Minetti, M. Federico, and M. Sanchez HIV-1 Nef regulates the release of superoxide anions from human macrophages Biochem J 390 2005 591 602